HIKAL
Back to All Ratios
|
HIKAL Last 5 Year EV/Core EBITDA History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EV/Core EBITDA(x) | 15.06 | 15.87 | 16.17 | 7.14 | 5.22 |
What is the latest EV/Core EBITDA ratio of HIKAL ?
Year | EV/Core EBITDA |
---|---|
Mar2024 | 15.06 |
Mar2023 | 15.87 |
Mar2022 | 16.17 |
Mar2021 | 7.14 |
Mar2020 | 5.22 |
How is EV/Core EBITDA of HIKAL Trending?
Years | EV/Core EBITDA | % Change | |
---|---|---|---|
Mar2024 | 15.06 | -5.10 | |
Mar2023 | 15.87 | -1.86 | |
Mar2022 | 16.17 | 126.47 | |
Mar2021 | 7.14 | 36.78 | |
Mar2020 | 5.22 | - |
Other Financial Ratios of HIKAL
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare EV/Core EBITDA ratio of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹5,119.4 Cr | -0.2% | 10.7% | 50.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹432,948.0 Cr | 0.3% | 0.2% | 46% | Stock Analytics | |
DIVIS LABORATORIES | ₹157,873.0 Cr | -2.7% | -0.1% | 58.9% | Stock Analytics | |
CIPLA | ₹116,809.0 Cr | -3% | -8.6% | 19% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,963.0 Cr | -0.1% | -3.4% | 7.2% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹98,173.2 Cr | 0.8% | 1.8% | 48.1% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | -0.2% |
10.7% |
50.2% |
SENSEX | -0.6% |
2.3% |
16.9% |
You may also like the below Video Courses